Sign up


Match Document Document Title
8815808 Modulation of activity of neurotrophins  
The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3...
8815814 Cosmetic composition containing oligopeptides  
The invention is directed to the cosmetic use of tetrapeptides according to formula (I) R1-Val-Leu-Leu-Lys-R2 (I) wherein R1 is linked to the NH2-terminal group of the peptide and is chosen from...
8815261 Composition for external application comprising aripiprazole and organic acid as active ingredients  
[Summary] An external preparation formulation superior in the transdermal absorbability has been desired as a new administration route of aripiprazole. Transdermal absorption of aripiprazole has...
8815233 Method for treating pervasive development disorders  
A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and...
8815810 Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain  
The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is...
8815803 Method for increasing body height comprising systemic administration of CNP-53  
This invention provides a composition for increasing a body height of a patient with short stature or an individual other than patients with short stature. More specifically, the invention...
8816046 Compositions and methods for CaMKII inhibitors and uses thereof  
Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further...
8815809 Cysteine protease inhibitors  
Compounds of Formula II whereinR1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; orR1a and R1b together define a saturated cyclic amine with 3-6 ring atoms;R2a and R2b are independently H, halo,...
8815511 Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate  
This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition...
8809278 Cyclic tetrapeptides  
Cyclic tetrapeptides that are kappa opioid receptor (KOR) antagonists can be used in therapeutic applications for treating, inhibiting, and/or preventing drug addiction, drug use, or drug seeking...
8809274 Adhesive hemostatic agent based on porcine atelocollagen and method for production thereof  
Disclosed is an adhesive hemostatic agent based on non-blood constituents including DOPA, able to strongly adhere to collagen fibers, and which comprises an antifibrinolytic agent in addition to an...
8809275 Peptoids and methods for treating alzheimer's disease  
Provided herein are peptoids capable of inhibiting or reversing amyloid β (Aβ) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at l...
8802630 Method of treating brain injury  
A novel use of a neuropeptide for treating brain injury in a subject in need thereof is provided. The present invention also provides various amenable routes of administering urocortin, that is,...
8802626 Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects  
Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with...
8802088 Mixture of peptide-bound tryptophan and polypeptide-bound tryptophan  
The present invention relates to a composition which comprises tryptophan whereby 10 to 90%, preferably 20 to 80% of the tryptophan is present as free tryptophan or peptide-bound tryptophan and 10...
8796214 Neurotrophic peptides  
The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1) and alternatively comprising an adamantyl group at the C- and/or N-terminal end....
8796213 Apoaequorin-containing compositions and methods of using same  
Compositions containing apoaequorin and methods for their use in treating symptoms and disorders related to calcium imbalances associated with, for example, sleep quality, energy quality, mood...
8796225 Regulation of immune responses by modulation of the function of antigen presenting cells  
The present invention relates to the use of chaperonin 10 to modulate the function of antigen presenting cells. More particularly the invention resides in the modulation of cell surface expression...
8796216 Suppression of neuroendocrine diseases  
The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumor cell, preferably...
8796215 Neurotrophic peptides  
The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO: 1) and alternatively comprising an adamantyl group at the C-and/or N-terminal end....
8796226 Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof  
Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the long acting pharmaceutical composition comprises a...
8790699 Foam-formed collagen strand  
Foam-formed collagen strands and methods for forming strands involve depositing a dispersed solution of an isolated cleaned, de-fatted, enzymatically-treated (or non-enzyme treated) human-derived...
8791072 Modulating neuromuscular junction density changes in botulinum-toxin treated tissue  
A method may include administering botulinum toxin to a tissue of a patient and administering a neuropeptide of the CRF family to the tissue of the patient. In some examples, the botulinum toxin is...
8791076 Agonists of neurotrophin receptors and their use as medicaments  
The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are...
8790698 Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects  
Techniques for treating visceral or parietal membrane and tissue defects include the application of a collagen biomatrix to the defect to repair and regenerate a visceral or parietal membrane, for...
8791071 Cartilage material  
Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage...
8785389 Polymeric collagen biomaterials  
This invention relates to the production of biomaterials from polymeric collagen (PC) and its seeding with cells and other components of biomaterials. Polymeric collagen is isolated from tissue,...
8785606 Compositions and methods for promoting neuronal outgrowth  
Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the...
8785391 Compound and method for treatment of alzheimer's disease and familial dementia  
An isolated protein is provided for use in treatment of a condition selected from the group consisting of Alzheimer's disease, familial Danish dementia and familial British dementia in a mammal,...
8785390 Methods for treatment of Alzheimer's disease  
An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor...
8778343 Antibodies that bind tau oligomers  
Embodiments of the invention are directed to compositions and methods related to Tau oligomers and Tau oligomer specific antibodies.
8778883 Foamy biomaterial for biological tissue repair  
A kit for producing a foamed biocompatible material includes a container configured to sustain a high pressure, and a tissue-repair composition placed in the container. The composition contains a...
8778884 Glioprotectant peptide for use in the treatment of amyotrophic lateral sclerosis (ALS) and methods related thereto  
The described invention relates to the use of the TAT-BH4 peptide for treating or preventing the progression of ALS. The methods include, postponing the appearance of symptoms and improving motor...
8772242 Therapy for enteric infections  
There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhea,...
8772241 Peptide and use thereof  
The present invention provides a peptide represented by formula (I) of X1-Leu-X2-Leu-X3 wherein X1 represents Glu or Asp, X2 represents His, Lys or Arg, X3 represents Asp or Glu, with Glu, Asp,...
8771689 Alpha B-crystallin as a therapy for ischemia or inflammation  
The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is...
8772225 Biomarkers for multiple sclerosis  
The present invention relates to the diagnosis of neurological disorders, more specifically to the diagnosis of multiple sclerosis. A biomarker panel is provided which can be used to detect if a...
8772238 Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer  
The invention provides methods for treatment of tissue factor (TF) mediated or associated diseases or processes, such as cancer, by administering at least an active fragment of an Ixolaris...
8765675 Use of calcitonin in osteoarthritis  
The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.
8765679 Extract and peptides derived from Oryza sativa Japonica Group and uses thereof  
The invention relates to isolated peptides derived from Oryza sativa Japonica Group, pharmaceutical compositions comprising same, and uses thereof for treating, preventing, ameliorating, and/or...
8759302 Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis  
A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps...
8758770 Alpha-MSH therapies for treatment of autoimmune disease  
Methods and compositions for the enteral treatment of autoimmune disease such a multiple sclerosis with polypeptide therapeutics. Enteral therapeutics comprise monomeric alpha-MSH polypeptides such...
8759297 Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns  
Provided herein are compositions for increasing transport of agents across the blood-brain barrier, in some embodiments in both directions, while allowing their activity once across the barrier to...
8758791 Highly compression resistant matrix with porous skeleton  
A highly compression resistant matrix is provided for implantation at or near a target tissue site beneath the skin. The matrix comprises a polymer and a ceramic skeleton. The compression...
8758806 Human lubrication gel  
Human lubricating gels, methods and kits for delivering a therapeutic agent to a target tissue site beneath the skin of a patient utilizing human lubricating gel are provided, the human lubricating...
8759296 Bone morphogenic protein binding peptide  
A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the overall osteogenic activity of rhBMP-2, increases the rate at which...
8754034 Structure-based design of peptide inhibitors of amyloid fibrillation  
The invention provides methods for designing peptides that inhibit aggregation in target polypeptides. The candidate inhibitory peptidic compounds have an oligomeric sequence that forms...
8754036 Method for treating neuropathic pain  
An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction...
8754044 Neuroprotection by hepatic cells and hepatocyte secretory factors  
The present invention relates to compositions and methods for neuroprotection. In particular, provided herein are compositions (e.g., hepatocyte secretory factors) for alleviating and/or protecting...
8754037 Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same  
Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor...